Obesity, overweight at diagnosis ups B-cell lymphoma prognosis

Share this article:
Obesity, Overweight at Diagnosis Ups B-Cell Lymphoma Prognosis
Obesity, Overweight at Diagnosis Ups B-Cell Lymphoma Prognosis

(HealthDay News) -- For U.S. veterans with diffuse large B-cell lymphoma (DLBCL), being overweight or obese at time of diagnosis correlates with improved survival, according to a study published online May 29 in the Journal of Clinical Oncology.

To investigate the association between body mass index (BMI) at diagnosis and overall survival, Kenneth R. Carson, M.D., from the St. Louis Veterans Affairs Medical Center, and colleagues conducted a retrospective cohort study involving 2,534 U.S. veterans diagnosed with DLBCL from 1998 to 2008.

The researchers found that the mean age at diagnosis was 68 years, and 64 percent of patients were overweight or obese. Compared with other BMI groups, obese patients were significantly younger, had significantly fewer B symptoms, and showed a trend toward lower-stage disease. Compared with normal-weight patients, Cox analysis showed decreased mortality for overweight and obese patients (hazard ratios, 0.73 and 0.68, respectively). Treatment during the rituximab era attenuated the mortality risk but did not impact the association between BMI and survival. One year before diagnosis, disease-related weight loss occurred in 29 percent of patients with weight data, but Cox analysis based on BMI one year before diagnosis showed a persistent association between overweight/obesity and reduced mortality risk.

"Being overweight or obese at the time of DLBCL diagnosis is associated with improved overall survival," the authors write. "Understanding the mechanisms responsible for this association will require further study."

One author disclosed a financial relationship with Genentech.

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Unplanned hospitalizations among gastrointestinal cancer patients common

Unplanned hospitalizations among gastrointestinal cancer patients common

Among elderly patients with gastrointestinal cancer, unplanned hospitalizations are common, according to online research.

70-Gene signature not likely to be cost-effective for breast cancer

70-Gene signature not likely to be cost-effective for ...

Findings in comparative economic analysis of patients with node-negative breast cancer showed the 70-gene signature is unlikely to be cost-effective for guiding adjuvant chemotherapy decision making.

Many clinicians feel mobile apps can improve patient outcomes

Many clinicians feel mobile apps can improve patient ...

Many physicians believe digital communication technologies, including mobile apps, can be of benefit to their patients.